Vaxart (NASDAQ:VXRT) Stock Passes Below Two Hundred Day Moving Average – Time to Sell?

Vaxart, Inc. (NASDAQ:VXRT) crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $0.40 and traded as low as $0.35. Vaxart shares last traded at $0.3660, with a volume of 711,986 shares trading hands.

Vaxart Stock Up 0.9%

The company has a market cap of $87.87 million, a P/E ratio of -1.36 and a beta of 0.88. The business has a 50-day moving average price of $0.36 and a two-hundred day moving average price of $0.40.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of VXRT. Creative Planning bought a new stake in shares of Vaxart during the second quarter worth approximately $33,000. Goldman Sachs Group Inc. bought a new stake in shares of Vaxart during the 1st quarter valued at $31,000. Virtu Financial LLC acquired a new position in shares of Vaxart in the 1st quarter valued at $56,000. Invesco Ltd. lifted its stake in shares of Vaxart by 93.1% in the 1st quarter. Invesco Ltd. now owns 146,366 shares of the biotechnology company’s stock valued at $60,000 after purchasing an additional 70,568 shares during the period. Finally, Raymond James Financial Inc. boosted its position in shares of Vaxart by 16.9% in the 2nd quarter. Raymond James Financial Inc. now owns 236,166 shares of the biotechnology company’s stock worth $107,000 after purchasing an additional 34,075 shares during the last quarter. Institutional investors own 18.05% of the company’s stock.

Vaxart Company Profile

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.